You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 133 No. 7, July 1997 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  STUDIES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (26)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Apoptotic and Proliferating Cells in Cutaneous Lymphoproliferative Diseases

Arata Kikuchi, MD, PhD; Takeji Nishikawa, MD, PhD

Arch Dermatol. 1997;133(7):829-833.


Abstract



Background
The cell production vs the cell loss rate is one of the most important parameters in evaluating growth and biological behavior of neoplasms. Individual cell disintegration in tissues, apoptosis, is a constant finding in various tumors and has been shown, by using several techniques, as a recognizable cell death that is different from necrosis.

Design
We studied the apoptosis-proliferation ratio in various lymphoproliferative disorders in the skin, including mycosis fungoides (MF), cutaneous T-cell lymphoma showing solid tumor mass (CTCL), B-cell lymphoma of the skin (BCL), lymphomatoid papulosis (LyP), and cutaneous pseudolymphoma by using terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP)-biotin nick end labeling (TUNEL), a newly developed method to detect internucleosomal breaks characteristic of apoptotic cells.

Setting
University referral center.

Patients
Fifty patients with cutaneous lymphoproliferative diseases.

Main Outcome Measures
Proliferation indexes and apoptosis index calculated by using immunohistochemical techniques.

Results
The proliferation indexes in pseudolymphoma, which were calculated by using immunohistochemical analyses with anti-proliferating cell nuclear antigen and anti-M1B-1 monoclonal antibodies, were significantly lower than the indexes of MF, CTCL, BCL, and LyP, whereas, the apoptosis index in Lyp was significantly higher than in any other lymphoproliferative diseases studied. The apoptosis-proliferation ratio in the tumor stage of MF, CTCL, and BCL was almost constant, but the ratios in LyP and the plaque stage of MF were significantly higher than in the other diseases studied.

Conclusions
The clinical behavior of each lymphoproliferative disease in the skin seemed to be reflected in the apoptosis and proliferation indexes. We conclude that these indexes may become useful factors in the determination of the diagnosis and the prognosis for patients with lymphoproliferative diseases.

Arch Dermatol. 1997;133:829-833



Author Affiliations



From the Department of Dermatology, Keio University School of Medicine, Tokyo, Japan. Dr Kikuchi is now with the Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Rate of Apoptosis in Feline Mammary Tumors is not Predictive of Postsurgical Survival
Sarli et al.
Journal of Veterinary Diagnostic Investigation 2003;15:115-122.
ABSTRACT  

A Novel Splice Variant of the Fas Gene in Patients with Cutaneous T-Cell Lymphoma
van Doorn et al.
Cancer Res. 2002;62:5389-5392.
ABSTRACT | FULL TEXT  

CD30-CD30 Ligand Interaction in Primary Cutaneous CD30+ T-Cell Lymphomas: A Clue to the Pathophysiology of Clinical Regression
Mori et al.
Blood 1999;94:3077-3083.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.